Immuneering Corp
IMRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316,952 | $2.1M | $2.3M |
| Operating income | −$59.4M | −$64.1M | −$58.4M | −$51.7M | −$33.9M | −$17.1M |
| Net income | −$56.0M | −$61.0M | −$53.5M | −$50.5M | −$33.5M | −$17.0M |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M | $38.4M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M | $2.8M |
| Equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M | −$22.5M |
| EPS (diluted) | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 | $-3.44 |
| Shares out. | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M | 5.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −25.6%
- Return on assets
- −24.2%
- Return on capital (ROCE)
- −26.8%
- Liabilities / assets
- 5.8%
- Debt / equity
- 0.06×
- Book value / share
- $4.96
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 16.03safe
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-06A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
- Phase 3Recruitingreadout ~2028-06Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Zeskind Benjamin J.Passive (13G)Jan 22, 2026
- Empery Asset Management, LpPassive (13G)Jan 15, 2026
- Fmr LlcPassive (13G)Oct 7, 2025
- Hbm Healthcare Investments (Cayman) Ltd.Passive (13G)Oct 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Neufeld Leah ROfficer — CHIEF PEOPLE OFFICER | Mar 13, 2026 | Grant | 3,628 | $4.29 |
| Brakewood Harold EugeneOfficer — Chief Business Officer | Jan 16, 2026 | Buy | 5,250 | $4.76 |
| Schall Thomas J.Director | Jan 15, 2026 | Buy | 21,645 | $4.67 |
| Hall Brett MatthewOfficer — CHIEF SCIENTIFIC OFFICER | Jan 15, 2026 | Buy | 2,298 | $4.57 |
| Neufeld Leah ROfficer — CHIEF PEOPLE OFFICER | Jan 13, 2026 | Buy | 2,626 | $4.15 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.9M | 14.9 | +4.1% |
| Apr 30, 2026 | 9.5M | 11.6 | -1.1% |
| Apr 15, 2026 | 9.6M | 13.2 | -6.7% |
| Mar 31, 2026 | 10.3M | 7.8 | -8.5% |
| Mar 13, 2026 | 11.3M | 13.1 | +1.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Results of operationsMay 15, 2026
- Results of operationsMar 6, 2026
- Other material eventJan 7, 2026
- Results of operationsNov 12, 2025
- Entered a material agreement · Other material eventSep 25, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventSep 24, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventAug 25, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.